The aim of this study is to demonstrate the clinical feasibility of quantitative low-count SPECT imaging for [225Ac]Ac-PSMA-I&T therapy of advanced prostate cancer and to provide a first image-based estimate of the radiation absorbed dose in critical organs and lesions. This evidence concerns the gene FOLH1 and prostate carcinoma.